Pharmacotherapy follow-up effects in the improvement of the therapeutic scheme in patients with biotechnology drugs and elevated economic impacts
- At: 2013 FIP Congress in Dublin (Ireland)
- Type: Poster
- By: PEDROZA-PASTRANA, Anamaria (Audifarma S.A., Bogota, Colombia)
- Co-author(s): Cuellar Saenz, Yenith Alexandra (Audifarma S.A., Bogota, Colombia)
Mendoza Arenas, Sandra Tatiana (Audifarma S.A., Bogota, Colombia)
Parrado, Yadira (Audifarma S.A., Bogota, Colombia)
The increasing prescription of drugs with short time on the market like biotechnology drugs (monoclonal antibody, tyrosine kinase inhibitor, hormones), as well as high economic and health impact drugs (fingolimod or cyclophosphamide), have prompted questions about their need, effectiveness and safety.
To improve results with.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.